Compounders Research Compare

Dianthus Therapeutics, Inc.(DNTH)

Biotechnology · New York, NY

$84.29-3.75 (-4.26%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

New York, NY

92 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Marino Garcia

View full financials

Price/FCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/FCF ratio is N/A as of 2026-10-06T19:51:49.609Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:51:49.609Z.

Quote observation: 2026-10-06T19:50:43.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 4,714,708,300
TTM free cash flow · period ending 2026-06-30: -155,709,000

FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9

P/E Ratio|FCF Growth|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DNTH Price/FCF Ratio Metrics

PRICE/FCF RATIO

N/A

DNTH Competitors' Price/FCF Ratio

Dianthus Therapeutics, Inc.

Current

Market Cap

$4.71B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Definium Therapeutics, Inc.

Market Cap

$4.71B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeStance Health Group, Inc.

Market Cap

$4.68B

Price/FCF Ratio

26.93

TTM Avg

23.99

3Y Avg

32.53

5Y Avg

32.53

Option Care Health, Inc.

Market Cap

$4.64B

Price/FCF Ratio

N/A

TTM Avg

17.05

3Y Avg

20.25

5Y Avg

24.33

BillionToOne, Inc.

Market Cap

$4.63B

Price/FCF Ratio

139.58

TTM Avg

194.41

3Y Avg

194.41

5Y Avg

194.41

Mirum Pharmaceuticals, Inc.

Market Cap

$4.80B

Price/FCF Ratio

N/A

TTM Avg

99.02

3Y Avg

99.02

5Y Avg

99.02

Oruka Therapeutics, Inc.

Market Cap

$4.82B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Erasca, Inc.

Market Cap

$4.96B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Indivior Pharmaceuticals Inc

Market Cap

$4.47B

Price/FCF Ratio

N/A

TTM Avg

30.17

3Y Avg

53.50

5Y Avg

47.42

Heartflow, Inc. Common Stock

Market Cap

$4.41B

Price/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/FCF RATIO	TTM	3Y	5Y
Dianthus Therapeutics, Inc. (DNTH)	$4.71B	N/A	N/A	N/A	N/A
Definium Therapeutics, Inc. (DFTX)vs ›	$4.71B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.68B	26.93	23.99	32.53	32.53
Option Care Health, Inc. (OPCH)vs ›	$4.64B	N/A	17.05	20.25	24.33
BillionToOne, Inc. (BLLN)vs ›	$4.63B	139.58	194.41	194.41	194.41
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.80B	N/A	99.02	99.02	99.02
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.82B	N/A	N/A	N/A	N/A
Erasca, Inc. (ERAS)vs ›	$4.96B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.47B	N/A	30.17	53.50	47.42
Heartflow, Inc. Common Stock (HTFL)vs ›	$4.41B	N/A	N/A	N/A	N/A

Free Cash Flow Valuation

P/FCF Ratio

N/A

FCF Yield

N/A

Price/FCF Ratio Formula & Definition

P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Growth Operating Margin All Metrics